The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study.

Anton L V AvanceñaJames G KahnElliot Marseille

Published in: Clinical drug investigation (2022)

Expanding access to MDMA-AT to patients with chronic and severe PTSD will provide substantial health and financial benefits. The precise magnitude is uncertain and will depend on the number of eligible patients and other inputs.

Keyphrases

public health
healthcare
end stage renal disease
mental health
ejection fraction
early onset
newly diagnosed
health information
chronic kidney disease
posttraumatic stress disorder
social support
drug induced
peritoneal dialysis
depressive symptoms
patient reported outcomes
patient reported
childhood cancer